Abstract
Lisocabtagene maraleucel (liso-cel) is one of the three US FDA-approved chimeric antigen receptor T-cell therapies for the treatment of relapsed/refractory (R/R) large B-cell lymphoma (LBCL). TRANSCEND is the landmark trial that led to the approval of liso-cel in the third-line setting for R/R diffuse LBCL, primary mediastinal B-cell lymphoma, follicular lymphoma grade 3B and transformed lymphoma. The TRANSFORM and PILOT studies evaluated the use of liso-cel in the second-line treatment of R/R LBCL. This review details the structure and manufacturing process of liso-cel that make it distinct from other approved chimeric antigen receptor constructs, outlines results from landmark trials of liso-cel in LBCL and discusses liso-cel toxicity.
Original language | English (US) |
---|---|
Pages (from-to) | 19-28 |
Number of pages | 10 |
Journal | Future Oncology |
Volume | 19 |
Issue number | 1 |
DOIs | |
State | Published - Jan 1 2023 |
Keywords
- CAR T-cell therapy
- large B-cell lymphoma
- lisocabtagene maraleucel
ASJC Scopus subject areas
- Oncology
- Cancer Research